Harter P, Trillsch F, Okamoto A, Reuss A, et al. Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Ann Oncol 2025 Dec 9:S0923-7534(25)06315-X. doi: 10.1016/j.annonc.2025.
PMID: 41380962